Iovance Biotherapeutics Inc (NASDAQ:IOVA) – Equities researchers at Jefferies Group issued their Q3 2018 earnings estimates for shares of Iovance Biotherapeutics in a research note issued to investors on Monday. Jefferies Group analyst B. Amin anticipates that the biotechnology company will post earnings per share of ($0.31) for the quarter. Jefferies Group currently has a “Buy” rating and a $31.00 target price on the stock. Jefferies Group also issued estimates for Iovance Biotherapeutics’ FY2018 earnings at ($1.22) EPS, FY2019 earnings at ($1.21) EPS, FY2020 earnings at ($1.29) EPS and FY2021 earnings at ($0.57) EPS.
A number of other brokerages have also recently commented on IOVA. BidaskClub cut shares of Iovance Biotherapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 22nd. ValuEngine upgraded shares of Iovance Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. HC Wainwright boosted their price objective on shares of Iovance Biotherapeutics from $16.00 to $22.00 and gave the company a “buy” rating in a research report on Thursday, January 25th. Oppenheimer boosted their price objective on shares of Iovance Biotherapeutics from $13.00 to $19.00 and gave the company an “outperform” rating in a research report on Wednesday, January 31st. Finally, Zacks Investment Research upgraded shares of Iovance Biotherapeutics from a “hold” rating to a “buy” rating and set a $10.00 price objective on the stock in a research report on Wednesday, January 17th. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Iovance Biotherapeutics presently has an average rating of “Buy” and a consensus price target of $19.72.
Iovance Biotherapeutics (IOVA) opened at $16.20 on Thursday. The company has a market cap of $1,538.47, a price-to-earnings ratio of -11.49 and a beta of 5.57. Iovance Biotherapeutics has a 52-week low of $4.45 and a 52-week high of $19.90.
Iovance Biotherapeutics (NASDAQ:IOVA) last issued its earnings results on Monday, March 12th. The biotechnology company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.04).
Several hedge funds have recently added to or reduced their stakes in IOVA. Parametric Portfolio Associates LLC purchased a new position in shares of Iovance Biotherapeutics in the second quarter valued at about $125,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Iovance Biotherapeutics in the third quarter valued at about $133,000. Ellington Management Group LLC increased its position in shares of Iovance Biotherapeutics by 39.1% in the fourth quarter. Ellington Management Group LLC now owns 19,200 shares of the biotechnology company’s stock valued at $154,000 after acquiring an additional 5,400 shares during the period. Teacher Retirement System of Texas purchased a new position in shares of Iovance Biotherapeutics in the fourth quarter valued at about $154,000. Finally, Jane Street Group LLC bought a new stake in shares of Iovance Biotherapeutics during the 3rd quarter valued at about $164,000. Hedge funds and other institutional investors own 67.82% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Analysts Offer Predictions for Iovance Biotherapeutics Inc’s Q3 2018 Earnings (IOVA)” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/03/16/analysts-offer-predictions-for-iovance-biotherapeutics-incs-q3-2018-earnings-iova.html.
About Iovance Biotherapeutics
Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.